Dyne Therapeutics (DYN) said Tuesday that the US Food and Drug Administration granted fast-track designation for its experimental therapy, DYNE-101, to treat a genetic neuromuscular disease, myotonic dystrophy type 1.
DYNE-101 is currently being evaluated in the ongoing phase 1/2 trial.
The company said it plans to submit for US accelerated approval in the first half of next year.
Shares of the company were up more than 4% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。